National Disaster Management Authority (India)

Eating Disorder Treatment Expert, Margherita Mascolo, MD, CEDS-S, Joins Inner Haven Wellness as Chief Medical Officer

Retrieved on: 
Thursday, August 24, 2023
National Disaster Management Authority (India), American Psychiatric Association, National Alliance, Denver Health Medical Center, Eating disorder, University, Malnutrition, Residential area, APA, History, Associate, From Every Stage, University of Colorado School of Medicine, SEES, Medical director, MD, Patient, Eating, Knowledge, Diagnosis, M.A, LPC, Medical device, Nursing, Medicine

MADISON, Wis., Aug. 24, 2023 /PRNewswire/ -- Inner Haven Wellness announces the appointment of Margherita Mascolo, MD, CEDS-S as Chief Medical Officer. With a history of dedicated healthcare leadership and clinical expertise, Dr. Mascolo will play a pivotal role in ensuring the organization delivers industry-leading treatment and achieves excellent patient outcomes. Dr. Mascolo has built eating disorder treatment programs at every level of care and she is known for her commitment to delivering compassionate, comprehensive, and cutting-edge care.

Key Points: 
  • She will leverage her 15 years of leadership experience in the eating disorder treatment field to ensure Inner Haven Wellness delivers industry-leading and evidence-based clinical care.
  • MADISON, Wis., Aug. 24, 2023 /PRNewswire/ -- Inner Haven Wellness announces the appointment of Margherita Mascolo, MD, CEDS-S as Chief Medical Officer.
  • Prior to Inner Haven Wellness, Dr. Mascolo was the Chief Medical Officer at a national multi-state eating disorder treatment company leading the medical care and medical operations at residential, day treatment, intensive outpatient, and virtual programs.
  • In her role as Chief Medical Officer, Dr. Mascolo will enhance Inner Haven Wellness' treatment plan by establishing medical standards, overseeing medical care, leading medical operations, and training clinical team members in evidence-based care for treating patients with eating disorders and comorbidities.

WeightWatchers to Acquire Sequence, a Digital Health Platform for Clinical Weight Management

Retrieved on: 
Monday, March 6, 2023
Sequence, McDonnell Aircraft Corporation, Learning, Science, Journal, Insurance, WW International, CPS, Acquisition, CM, Growth, Obesity, Overweight, Education, Bai He, William Edward Fitch, Endocrine Society, Food and Drug Administration, The Journal of Clinical Endocrinology and Metabolism, The Obesity Society, Entrepreneurship, FDA, Metabolism, National Disaster Management Authority (India), Doctor of Philosophy, American College, OMA, Nursing, Cryptocurrency, Pharmaceutical industry, Security (finance), Teahouse, Soft drink, Medical device, WW

Clinical interventions require better education, access, care management, community and the integration of a complementary lifestyle program for best results.

Key Points: 
  • Clinical interventions require better education, access, care management, community and the integration of a complementary lifestyle program for best results.
  • “As we build out our clinical weight management pathway, we will be learning and likely tailoring our nutrition program for this distinct member journey.
  • “WeightWatchers is the most studied and trusted behavior change program, and their customer-centric approach to livable, sustainable, science-backed weight management is unparalleled.
  • To learn more about Sequence, please visit https://www.joinsequence.com/ and to learn more about WeightWatchers’ entry into clinical weight management, please visit: https://www.weightwatchers.com/us/medical-weight-loss .

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

Retrieved on: 
Tuesday, February 28, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, NGS, American College, Workflow, American College of Medical Genetics and Genomics, Gene, Pregnancy, Risk, Algorithm, Patient, Informatics, Medical genetics, ACMG, Carrier, Beacon, National Disaster Management Authority (India), Saint-Fulgent, Sequence homology, Woman, ACOG, Thornburgh v. American College of Obstetricians & Gynecologists, Vaccine, Genomics, Gynaecology

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel.
  • The ACMG list includes genes with carrier frequency of >1/200 for autosomal recessive conditions and disease prevalence of >1/40,000 for X-linked conditions.
  • “This is an important product launch for our company and a big step forward in carrier screening,” said Brandon Perthuis, Fulgent’s Chief Commercial Officer.
  • The American College of Obstetricians and Gynecologists (ACOG) recommends offering carrier screening to all women who are considering pregnancy, regardless of ethnicity or family history.

Miguel-Angel Perales, M.D., Named 2023 - 2024 President of ASTCT

Retrieved on: 
Monday, February 20, 2023
Society, Science, National Disaster Management Authority (India), Weill Cornell Medicine, Publication, Patient, Committee, Research, Bone marrow, Haematopoietic system, Risk, Memorial Sloan Kettering Cancer Center, Graft-versus-host disease, Immune system, Council of Military Education Committees of the Universities of the United Kingdom, Transplant, Education Committee, Dentistry, Medicine

CHICAGO, Feb. 20, 2023 (GLOBE NEWSWIRE) -- The American Society for Transplantation and Cellular Therapy (ASTCT) announced Miguel-Angel Perales, M.D., as the President of the Society in 2023 - 2024.

Key Points: 
  • CHICAGO, Feb. 20, 2023 (GLOBE NEWSWIRE) -- The American Society for Transplantation and Cellular Therapy (ASTCT) announced Miguel-Angel Perales, M.D., as the President of the Society in 2023 - 2024.
  • Dr. Perales first served on the Board of Directors in 2017 and has been a member of ASTCT since 2001.
  • "I have enjoyed serving on the ASTCT Board of Directors, and I am honored to serve as President this year," stated Dr. Perales.
  • In addition to Dr. Perales, below is the complete list of 2023 - 2024 ASTCT Board of Directors:

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

Retrieved on: 
Wednesday, October 12, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ACSL4, Non-alcoholic fatty liver disease, Pioglitazone, Euronext Paris, ADPKD, Liver cancer, American Association, Association, Adrenoleukodystrophy, Biomarker, Adenosine, American Association for the Study of Liver Diseases, QD, Lists of diseases, Fibrosis, Inflammation, Company, Obesity, Bone, Degenerative disease, Cirrhosis, European Association for the Study of the Liver, ALD, Liver failure, FDA, Time, Risk, Deuterium, EASL, Edema, Weight gain, AASLD, Type 2 diabetes, Disease, Triglyceride, Cholesterol, Histology, Partnership, Human, National Disaster Management Authority (India), AMPK, Safety, MPC, Forward-looking statement, Fatty liver disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Copper, Euronext, Liver, Imeglimin, Patient

The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.

Key Points: 
  • The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.
  • Analysis of histologic changes was based on paired liver biopsies in PXL065 vs. placebo-treated NASH patients before and after the 36-week treatment period.
  • Across all PXL065 treatment arms (pooled data), 39% of patients had fibrosis improvement by 1 stage without worsening NASH (%) vs. 17% with placebo.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Labroots to Host Diagnostica Stago, Inc.'s Latest Webinar in the Ongoing Stago EdVantage Virtual University, September 7, 2022

Retrieved on: 
Thursday, August 25, 2022
Hemostasis, Literature, University, National Disaster Management Authority (India), Research, Internal medicine, Anticoagulant, Heparin, Pharming, Sanford, Rivaroxaban, Learning, Department, SD, Science, DOAC, Labroots, Sanford USD Medical Center, Social, News, University of South Dakota Sanford School of Medicine, Industry, Thrombosis, BCPS, Patient, Medical device, Online shopping

PARSIPPANY, N.J., Aug. 25, 2022 /PRNewswire-PRWeb/ -- August 25, 2022 (Parsippany, NJ) Diagnostica Stago, Inc., currently the only independent international group in the In Vitro Diagnostics industry dedicated to hemostasis and thrombosis exploration, has invited Michael P. Gulseth, Pharm.D., BCPS, FMSHP, FASHP, Anticoagulation Stewardship Director at Sanford USD Medical Center in Sioux Falls, SD, and Clinical Associate Professor, Department of Internal Medicine, at the University of South Dakota Sanford School of Medicine, to present his work in the latest webinar for the ongoing Stago EdVantage Virtual University, September 7th, 2022. The webinar titled, "Managing Direct Oral Anticoagulant Inhibitor to Heparin Conversion; Heparin Anti-Xa assay or aPTT?", will cover a recently published comprehensive practice guideline on how to manage patient transitions from a direct oral anticoagulant to a heparin infusion, along with an assessment of its performance versus an alternative strategy.

Key Points: 
  • The webinar titled, " Managing Direct Oral Anticoagulant Inhibitor to Heparin Conversion; Heparin Anti-Xa assay or aPTT?
  • To overcome these challenges, clinicians and their laboratory partners have been developing optimal processes to manage transitions to heparin infusions.
  • With more than 20 on-demand webinars, Stago EdVantage Virtual University is the longest-running virtual event hosted on the Labroots platform.
  • For more information about Dr. Gulseth's webinar, "Managing Direct Oral Anticoagulant Inhibitor to Heparin Conversion; Heparin Anti-Xa assay or aPTT?

NEW RESEARCH FINDS WEIGHTWATCHERS APPROACH RESULTS IN SIGNIFICANTLY GREATER WEIGHT LOSS THAN DO-IT-YOURSELF

Retrieved on: 
Monday, August 22, 2022
Medical Research Council, WW International, National Health and Medical Research Council, Guideline, Chapel Hill, American College of Cardiology, University, National Health, Obesity, WW, JAMA Network Open, University of North Carolina at Chapel Hill, Ageing, Doctor of Philosophy, Participation, The Obesity Society, American Heart Association, Physician, Behavior, American College, Science, Clinical study design, Tate, MD, Prevalence, Social media, Weight loss, Blood pressure, News, Data collection, Adult, DIY, USPSTF, Overweight, VA, Patient, National Disaster Management Authority (India), Dietary supplement, Pharmaceutical industry

NEW YORK, Aug. 22, 2022 /PRNewswire/ -- A new randomized clinical trial published in JAMA Network Open found that those engaged in WeightWatchers, a commercially available weight loss program, lost more than twice the amount of weight than those who tried to lose weight on their own. Those randomly assigned to WeightWatchers were also more likely to achieve clinically significant weight loss of five percent at three and twelve months, which can help lead to health benefits - including improvements in blood pressure, blood cholesterol and blood sugar.1

Key Points: 
  • As a result, the findings also suggest that programs with lower demands for self-monitoring of nutritious foods can produce clinically significant weight loss.
  • However, despite this guidance, most people try to lose weight on their own rather than choosing scientifically proven approaches.
  • We're also encouraged that our new approach - where you don't have to track everything you eat and drink - leads to clinically significant weight loss."
  • Through our comprehensive tools, expert Coaches and community, members follow our proven, sustainable, science-based program focused on weight loss.

Philips announces positive three-year clinical research results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial

Retrieved on: 
Monday, June 13, 2022
Consensus, TLS, Ulcer, Human, Committee, National Heart, Lung, and Blood Institute, American Association, Quality of life, Sale, Interventions, NYSE, Society of Interventional Radiology, Freedom, Medicine, Ischemia, National Disaster Management Authority (India), Interventional radiology, Amputation, III, Obstruction, Food, Society, Tack, BTK, Lung, Association, PAD, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Knee, IVUS, University, DCB, TLR, University of North Carolina at Charlotte, Chapel Hill, Dissection, Disease, AEX, FDA, Bed, Biology, TOBA, Clinical trial, CLI, PHG, Moyamoya disease, Transatlantic, Safety, Pharmaceutical industry, Medical imaging, Medical device, EU

If left untreated, 50% of patients with CLI will undergo an amputation or die within the first year [1].

Key Points: 
  • If left untreated, 50% of patients with CLI will undergo an amputation or die within the first year [1].
  • The TOBA II BTK trial studied the safety and efficacy of post-angioplasty dissection repair using the Philips Tack endovascular system in patients with CLI and infrapopliteal disease.
  • The Tack endovascular system is a unique specialized implantable device to optimize the treatment of dissections in patients with CLI.
  • Philips has previously reported data from the TOBA II and III studies, which evaluated the Tack endovascular system for superficial femoral and proximal popliteal artery dissection repair following uncoated balloon angioplasty and/or drug-coated balloon (DCB) angioplasty.

BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Retrieved on: 
Tuesday, May 10, 2022
Technology, Research, Clinical Trials, Software, Biotechnology, Health, General Health, Science, Oncology, Journal of the National Comprehensive Cancer Network, Economics, Standard of care, RNA-Seq, Twitter, Health, RNA, Medicine, Biomarker, NCCN, Physician, Cancer, Patient, Neoplasm, Diagnosis, DNA, WES, MD, Nursing, Education, National Disaster Management Authority (India), Research, Medical imaging

BostonGene today announced a strategic agreement with the National Comprehensive Cancer Network (NCCN) to integrate its Clinical Practice Guidelines into the BostonGene Tumor Portrait Test reports.

Key Points: 
  • BostonGene today announced a strategic agreement with the National Comprehensive Cancer Network (NCCN) to integrate its Clinical Practice Guidelines into the BostonGene Tumor Portrait Test reports.
  • By integrating genomic and transcriptomic analysis, in concert with the patients clinical history, the BostonGene Tumor Portrait Test provides information regarding biomarkers associated with response/resistance to therapies or therapeutic combinations, NCCN Guidelines treatment recommendations, and ongoing clinical trials.
  • NCCN is committed to maintaining clinical practice guidelines that include actionable biomarkers and recommendations for cancer treatment options based upon biomarker results.
  • Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) and other initiatives.

Carbide More than Triples Security Awareness Training Content Within Platform; Introduces Specific Tracks for CCPA, HIPAA, PCI DSS, and GDPR

Retrieved on: 
Wednesday, May 4, 2022
Partnership, Privacy, Carbide, Outline, Industry, Compliance, Software as a service, DNA, Prevalence, CEO, Awareness, GLOBE, Risk, Organization, National Disaster Management Authority (India), Risk management, Online shopping

Through a strategic partnership with NINJIO , the premier customers choice cybersecurity awareness training company, Carbide has enhanced and expanded its library of security and privacy training resources available directly in the platform.

Key Points: 
  • Through a strategic partnership with NINJIO , the premier customers choice cybersecurity awareness training company, Carbide has enhanced and expanded its library of security and privacy training resources available directly in the platform.
  • Carbide is committed to helping fast-growing companies embed security and privacy into the DNA of their organizations.
  • Regular security awareness training and testing is a critical requirement in nearly every security framework, privacy regulation, and industry best practice guideline.
  • However, employees often dont take security training seriously due to the prevalence of boring videos that restate the obvious.